Bookmark

Add to MyYahoo RSS

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

3 hrs ago | CNN

Stock Picks: Three Biotech Big-Caps to Look At

The recent biotech price correction may have sent some investors running for the hills, but not everyone is losing faith on the highly profitable sector.

Comment?

Related Topix: Biotech, Science / Technology, Financial Markets, Medicine, Gilead Sciences, Healthcare Industry, Startups, Search Engines, HIV/AIDS, Health

Tue Apr 15, 2014

GlobeSt.com

Silicon Valley Apt. Moves in 1031 Exchange

Join us at the The Encore Las Vegas in Las Vegas, NV, where we will bring together the top student housing executives from across the country who will cover the hottest topics in financing, investment, brokerage, development and property management, our industry leaders will give the highest level views on the sector - at RealShare STUDENT HOUSING ... (more)

Comment?

Related Topix: us Travel, Travel, San Mateo, CA, Palo Alto, CA, Startups, Electronic Arts

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

2... )--Gilead Sciences, Inc. announced today that its first quarter 2014 financial results will be released on Tuesday, April 22, at 4:05 p.m. Eastern ... )--Diodes Incorporated , a leading global manufacturer and supplier of high-quality application specific standard products within the broad discrete, logic... )--Q2 Holdings, Inc. announced ... (more)

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Semiconductors, Diodes, Electronics, Diodes Incorporated, Nuevo, CA

Business Wire

Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014

At 4:15 p.m. Eastern Time, Gilead's management will host a conference call to discuss the company's financial results for the first quarter 2014 and provide a general business update.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals

ThinkProgress

'Major Breakthrough' In Hepatitis C Treatment Is Way Too Expensive For Anyone To Afford

Solvadi, a new drug that can help combat hepatitis C, is being hailed as a " turning point " in the treatment of the liver disease.

Comment?

Related Topix: Hepatitis, Health, Medicine, Gilead Sciences, Biotech, Healthcare Industry, Startups, US News, US House of Representatives, Democrat, US Politics, Henry Waxman, Frank Pallone, Diana DeGette

Mon Apr 14, 2014

Sympatico Finance

Biotech stocks stronger than Nasdaq's latest weakness [04-14-14 12:30 PM]

Activist investor Daniel Loeb, who is fighting to win control of three board seats at Sotheby's , on Monday raised the temperature by saying the current board has failed and that its attacks on him are "false" and "misleading."

Comment?

Related Topix: Financial Markets, Retail, Auctions, Sothebys Holdings, Startups, CGI Pharmaceuticals

Seeking Alpha

Gilead Sciences' Solvadi Is A Game Changer

Antiviral products generate about 86% of the total revenues, and the product group is also vitally important for the company's top and bottom line growth.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, HIV/AIDS, Health

Business Wire

AHF: Anti-Gilead Drug Pricing Campaign Picks Up Steam

Bloomberg reports that pharmacy benefits manager Express Scripts, which handles drug reimbursement for a big chunk of the U.S. private insurance market, says it's forming a coalition to refuse to use Sovaldi after a competitor hits the market.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Social Solutions, Startups, IGN Entertainment, Fox Interactive Media, US Politics, US News, US House of Representatives, Henry Waxman, Democrat

CNN

Hopes pinned on biotech firms' development of novel treatments

When it comes to biotech stocks, patience is the key. Investors need to hold on for the long-term while learning more about how their stocks will become more valuable in the future.

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Amgen, Healthcare Industry, Gilead Sciences, Startups, Celgene, Cancer, Health

Sat Apr 12, 2014

SFGate

Cost of Gilead's hepatitis C pill, Sovaldi, spurs revolt

Orlando Chavez, who works at the Berkeley Free Clinic, was cured of hepatitis C in 2005 after painful treatment and says he would have jumped on Gilead's new drug, Sovaldi, at any price.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Hepatitis, Health, Berkeley, CA, Startups, CGI Pharmaceuticals, Science / Technology

SiliconValley.com

Gilead

The health and biomedical industries in Silicon Valley saw a 15.5 percent increase in profits in 2013 -- representing $4.4 billion -- but, perhaps more importantly, venture capital also began flowing after nearly five years of lean investments.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Foster City, CA, Startups, CGI Pharmaceuticals

TheStreet.com

Drying Stimulus Tap Is Sore Spot for Tech Stocks

NEW YORK -- The drying stimulus tap rather than stretched valuations has been the trigger for recent selling in tech and biotech shares, some managers argue, claiming this makes another tech sector crash unlikely.

Comment?

Related Topix: Financial Markets, TheStreetcom, Media, TheStreet, Computers, Startups, CGI Pharmaceuticals

Fri Apr 11, 2014

The Washington Post

Developing Countries Seek Lower Cost for Sovaldi

Developing countries are seeking to pay as little as 1 percent of the $84,000 price Gilead Sciences Inc. is charging U.S. patients for its new hepatitis C drug.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Hepatitis, Health, Foster City, CA, Business News

Forbes.com

Friday's ETF Movers: BBH, XME

In trading on Friday, the Biotech ETF is outperforming other ETFs, up about 0.4% on the day.

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry, Incyte, Financial Markets

TheStreet.com

Why Gilead Sciences (GILD) Stock Is Up Today

The bump follows a Reuters report that the Texas Health and Human Services Commission will reconsider its restrictive recommendation to Medicaid concerning Gilead Science's hepatitis C drug treatment, Sovaldi, due to the drug's high costs.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Texas Government, Texas, Medicaid, Health, Hepatitis, Warren Buffett

Barron's

Biotech: Like Lambs to the Slaughter

The iShares Nasdaq Biotech ETF fell 5.6% to $221.89 today, while the SPDR S&P Biotechnology ETF dropped 6.5% to $129.79.

Comment?

Related Topix: Biotech, Science / Technology, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Amgen, Celgene

Information Technology

Gilead's Sovaldi Demonstrates Efficacy and Safety Among Chronic...

Gilead Sciences, Inc. today announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi 400 mg was administered for the treatment of chronic hepatitis C virus infection in patients with advanced liver disease.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, CGI Pharmaceuticals, Hepatitis, Health

The Campbell Reporter

Biz Break: Silicon Valley tech stocks slaughtered ahead of earnings reports

Traders Kevin Lodewick, left, and Timothy Nick work on the floor of the New York Stock Exchange Thursday, April 10, 2014.

Comment?

Related Topix: Financial Markets, Biotech, Science / Technology, Social Software, Redwood City, CA, Startups, CGI Pharmaceuticals

Thu Apr 10, 2014

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Gilead anuncia resultados de Fase 2 de dos regmenes basados en sofosbuvir totalmente orales en fase de investigacin para el tratamiento de la hepatitis C crnica )--Gilead Sciences, Inc. ha anunciado los datos de dos estudios de Fase 2 que evaluan regimenes totalmente orales en fase de investigacion que contienen el inh... )--Law office of Brodsky & ... (more)

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, United Online, Telecom, Computers, IT Services, Nielsen, Financial Markets, Buncombe County, NC

AmericanBankingNews.com

Gilead Sciences Target of Unusually High Options Trading

Gilead Sciences was the recipient of some unusual options trading on Thursday. Traders purchased 40,074 put options on the stock, AnalystRatings.Net reports.

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, Healthcare Industry

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••
•••